Bert Junno is co-founder, CEO and board member of Gabather since 2014. He is co-founder of the life science companies: WntResearch AB (public), Galecto Biotech AB, Aptahem AB (public) and Cyxone AB. He serves on the advisory board of the Swedish patent office since 2010. Bert Junno has previous management and board level experience from several European and US based companies in fields of electronics, biotech and IT. Bert Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University.
Mogens Nielsen, Candidatus scientiarum (Master of Science), served as Professor and head of the Research Institute of Biological Psychiatry, Sct. Hans Hospital, and the Biological department in Roskilde between 1971 and 1999. He has more than 180 publications and has served as guest professor at several international universities and as an affiliate with the University of Pharmaceutical Sciences in Copenhagen. He is a member of the editorial board of the Open Journal of Medicinal Chemistry. He received the Lundbeck Award in 1982. He is also Professor Honoris Causa at Shanxi Academy of TCM, Xian, China.
Ola Skanung has a Master of business and economics with many years of experience as CFO and working with start-ups and growth projects within the private as well as with state and regional development actors.
Johanna has extensive experience within areas such as project leader, consultant manager as well as drug consultant and product specialist at Pfizer and Bayer. She also has an extensive background as a nurse in areas such as intensive and dialysis care as well as cardiac and chest medicine. Johanna is a trained nurse with additional training in intensive care and has a bachelor’s degree as behaviourist within the social psychology area.
Principal Scientist: Dr Michael-Robin Witt holds a Ph.D. in Neuropharmacology from the Royal School of Pharmacy, Copenhagen, Denmark. He has published more than 50 publications in peer-reviewed scientific journals. Following 12 years in academic research, at the Brain Research Institute, St. Hans Hospital, Roskilde, Denmark. MRW has held senior line and project management positions in Scandinavian Biotech companies including Neurosearch AB (1999-2000), AstraZeneca R&D (2000-2003), KaroBio AB (2003-2007). In 2007, MRW co-founded Axcentua Pharmaceuticals AB, acting as CSO for 5 years before joining Lead Discovery Malaysia in 2012 where he currently holds the positions of CEO & CSO. MRW joined Gabather AB in September 2014 and was appointed Principal Scientist in October 2015.
Dr. Stefan Rehnmark holds a PhD in Physiology from the Wenner-Gren Institute, Stockholm University, where he also is appointed Associate Professor. After more than 10 years of academic research he moved to the Biotech industry, where he has been working for 18 years, holding several positions, such as Head of Molecular Biology, Head of Pharmacology, Project Manager and Principal Scientist. In 2007, he co-founded Axcentua Pharmaceuticals, where he served as CSO and CEO. In 2014, he co-founded Noviga Research, a Biotech company active in the development of oncology therapeutics. He joined Gabather AB as Principal Scientist in August 2016.
Administration and Economics: Malin works with administration and economics in the company. On the side she is also currently in the final steps of her Business and Administration Bachelor at Lund University with a specialization in Leadership and Management.
More than 25 years of experience from management, business development and finance in the Life Science Industry as well as the global chemical business. Key focus has been to commercialise product innovations in small start ups, mid size and large organisations. He has a deep knowledge in building teams and organisations, forming and managing strategic alliances, fund raising and most aspects of product development in the life science arena. Furthermore through 12 years as the CEO of a public listed company strong experiences in legal affairs, corporate governance and investor relations have been accumulated.
Olov Sterner is an organic chemist specializing in the science of biologically active secondary metabolites. He was awarded the PhD degree in 1985, and after two years as a postoctoral fellow at the University of Bonn in Germany he got a position as researcher at Lund University. 1990 he became lecturer in organic chemistry, and since 1999 he is professor. His research efforts have until now resulted in more than 350 scientific publications in international journals, 23 patent applications and patents, and many conference contributions. He has, alone or with colleagues, written several textbooks in organic chemistry and chemical toxicology, and he is currently the head of the Department of Chemistry.
BG Svensson holds an MSc in Economics from Lund University. He has been hired at Lund University since 2003, today as a senior advisor at LU Holding AB. Current board member positions: Director at Gabather AB, director Nares AB, director at Lunicore Studentkonsult AB, member of advisory consult, Marint Center Simrishamn. BG has also acted as: CEO at Lunds Universitets Utvecklings AB, CEO at Connect Skåne, CEO Science Village Scandinavia AB. Additionally, he has held various leading positions within the bank and finance world, both domestic and international.
Gunilla Ekström became member of the board at Gabather in 2016. Gunilla Ekström is a doctor and attained her PhD from Karolinska Institutet (KI) where she also is an associate professor in biochemical toxicology. She has more than 25 years experience from leading positions in pharmaceutical development in AstraZeneca, Orexo and Karolinska Development, where she had both strategic and operational responsibility for large development teams working with pre-clinical research as well as clinical pharmaceutical development. During her time at AstraZeneca she was a member of the therapeutical area Neurosciences management team, leading a portfolio organisation developing analgesic drug candidates from pre-clinical to clinical studies. Gunilla Ekström also has operational assignments in various SMEs.